CONCISE REPORT

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry

Christopher P Denton,1 Thomas Krieg,2 Loic Guillevin,3 Barbara Schwierin,4 Daniel Rosenberg,4 Mariabeth Silkey,4 Maurice Zultak,4 Marco Matucci-Cerinic5

ABSTRACT

Objectives The Digital Ulcers Outcome (DUO) Registry was designed to describe the clinical and antibody characteristics, disease course and outcomes of patients with digital ulcers associated with systemic sclerosis (SSc).

Methods The DUO Registry is a European, prospective, multicentre, observational, registry of SSc patients with ongoing digital ulcer disease, irrespective of treatment regimen. Data collected included demographics, SSc duration, SSc subset, internal organ manifestations, autoantibodies, previous and ongoing interventions and complications related to digital ulcers.

Results Up to 19 November 2010 a total of 2439 patients had enrolled into the registry. Most were classified as either limited cutaneous SSc (lcSSc; 52.2%) or diffuse cutaneous SSc (dcSSc; 36.9%). Digital ulcers developed earlier in patients with dcSSc compared with lcSSc. Almost all patients (95.7%) tested positive for antinuclear antibodies, 45.2% for anti-scleroderma-70 and 43.8% for anticientromere antibodies (ACA). The first digital ulcer in the anti-scleroderma-70-positive patient cohort occurred approximately 5 years earlier than the ACA-positive patient group.

Conclusions This study provides data from a large cohort of SSc patients with a history of digital ulcers. The early occurrence and high frequency of digital ulcer complications are especially seen in patients with dcSSc and/or anti-scleroderma-70 antibodies.

Systemic sclerosis (SSc) is a multisystem autoimmune disease characterised by microvascular damage and excessive fibrosis of the skin and various internal organs. Limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) subsets are also associated with the presence of a number of autoantibodies, the expression of which can be useful in the diagnosis, prognosis and SSc disease management.

The European Medicines Agency (EMA) requested the establishment of a prospective registry of patients with ongoing digital ulcers associated with SSc as a licensing requirement for bosentan in this indication. The Digital Ulcers Outcome (DUO) Registry enrols patients with digital ulcer disease regardless of their treatment status; however, a large proportion are receiving bosentan. This study provides valuable insights into this patient group and here we describe the clinical and autoantibody characteristics of these patients at enrolment.

METHODS

The DUO Registry was initiated in April 2008 as an EMA postapproval commitment (after approval of a new indication for bosentan ‘to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease’). Participating centres received approval from relevant national and local ethics committees, data protection and health authorities. In line with an observational study design, physicians were asked to enter all consenting consecutive patients with ongoing digital ulcers associated with SSc, irrespective of treatment regimen. Patients received standard medical care and follow-up as determined by their physician. Data definitions were informed by literature and scientific committee consensus. Data collection included demographics, SSc disease duration, underlying disease classification (lcSSc, dcSSc, overlap SSc/mixed connective tissue disease and other), internal organ manifestations, autoantibodies, history of interventions/complications related to digital ulcers, ongoing complications related to digital ulcers, and ongoing medications and functional assessment based on a disease-specific questionnaire. The presence of antinuclear antibodies, anti-scleroderma-70 antibodies, anticientromere antibodies (ACA), anti-RNA polymerase 3, anti-U1 ribonucleoprotein and anti-U5 ribonucleoprotein were recorded. All serology tests and other data collection parameters were collected if performed. Quality assurance comprised automatic online quality checks and annual source data verification on 10% of the patients.

Data analysis

Enrolment data for the antibody subsets were analysed cross-sectionally for differences by group. SAS statistical software was used for analysing the data. Descriptive statistics (mean, median, SD, 95% CI, minimum, maximum) are provided for numerical variables. Categorical variables are summarised by counts and percentages and 95% CI.

RESULTS

As of 19 November 2010, a total of 2439 patients had been enrolled into the DUO Registry from 271 participating centres in 18 European countries (Austria, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland and UK).

Correspondence to
Christopher P Denton, Centre for Rheumatology and Connective Tissue Diseases, Department of Inflammation, Division of Medicine, UCL Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK; cdenton@medsch.ucl.ac.uk

Accepted 11 December 2011
Received 19 August 2011
### Table 1

<table>
<thead>
<tr>
<th>Antibody subset</th>
<th>ANA* (N=2085)</th>
<th>Anti-scl-70 (N=854)</th>
<th>ACA (N=775)</th>
<th>Anti-U1 RNP (N=120)</th>
<th>Anti-U3 RNP (N=39)</th>
<th>Anti-RNA Pol 3 (N=86)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tested positive/tests performed (%)</td>
<td>2085/2179 (95.7)</td>
<td>854/1888 (45.2)</td>
<td>86/867 (9.9)</td>
<td>775/1778 (43.6)</td>
<td>120/1243 (9.7)</td>
<td>39/799 (4.9)</td>
</tr>
<tr>
<td>Female, n/N (%)</td>
<td>1719/2085 (82.4)</td>
<td>676/854 (79.2)</td>
<td>70/86 (81.4)</td>
<td>677/775 (87.4)</td>
<td>91/120 (75.8)</td>
<td>31/39 (29.5)</td>
</tr>
<tr>
<td>dcSSc, n/N (%)</td>
<td>1071/2070 (51.7)</td>
<td>249/894 (28.6)</td>
<td>28/85 (33.0)</td>
<td>14/85 (16.5)</td>
<td>14/85 (16.5)</td>
<td>6/38 (15.8)</td>
</tr>
<tr>
<td>lcSSc, n/N (%)</td>
<td>1071/2070 (51.7)</td>
<td>249/894 (28.6)</td>
<td>28/85 (33.0)</td>
<td>14/85 (16.5)</td>
<td>14/85 (16.5)</td>
<td>6/38 (15.8)</td>
</tr>
<tr>
<td>Overlap SSc/mCTD, n/N (%)</td>
<td>1071/2070 (51.7)</td>
<td>249/894 (28.6)</td>
<td>28/85 (33.0)</td>
<td>14/85 (16.5)</td>
<td>14/85 (16.5)</td>
<td>6/38 (15.8)</td>
</tr>
<tr>
<td>Time from onset of RP to first digital ulcer, years, mean (95% CI)</td>
<td>6.6 (6.2 to 7.0)</td>
<td>6.0 (5.4 to 6.6)</td>
<td>6.1 (4.4 to 7.8)</td>
<td>8.1 (7.3 to 9.0)</td>
<td>6.5 (4.9 to 8.0)</td>
<td>6.9 (3.5 to 10.4)</td>
</tr>
<tr>
<td>Time from first non-RP to first digital ulcer manifestation, years, mean (95% CI)</td>
<td>3.6 (3.3 to 3.9)</td>
<td>3.2 (2.9 to 3.6)</td>
<td>3.2 (2.9 to 3.6)</td>
<td>3.6 (3.3 to 3.9)</td>
<td>3.6 (3.3 to 3.9)</td>
<td>3.6 (3.3 to 3.9)</td>
</tr>
</tbody>
</table>

*Antibody subsets are not mutually exclusive: one patient can have several antibodies and therefore contribute to several groups. The denominator N varies according to the number of available observations.

### Antibody distribution

Almost all, 95.7% (2085/2179) of patients tested were positive for antinuclear antibodies, 45.2% (854/1888) for anti-scleroderma-70 antibodies, 43.6% (775/1778) for ACA, 9.9% (86/867) for anti-RNA polymerase 3, 9.7% (120/1243) for anti-U1 ribonucleoprotein and 4.9% (39/799) for anti-U3 ribonucleoprotein. Few patients had a combination of antibodies. The combination with the highest occurrence was anti-scleroderma-70 plus ACA, 2.3% (56/2439), followed by anti-scleroderma-70 plus anti-U1 ribonucleoprotein, 1.8% (43/2439), anti-scleroderma-70 plus anti-RNA polymerase 3, 1.5% (34/2439), ACA plus anti-U1 ribonucleoprotein, 1.4% (34/2439), ACA plus anti-RNA polymerase 3, 1.4% (34/2439) and anti-U1 ribonucleoprotein plus anti-U3 ribonucleoprotein, 1.3% (31/2439).

### SSc disease characteristics by antibody status

Patients positive for ACA were predominantly classified as lcSSc (82.9%; table 1). From the patients positive for anti-scleroderma-70 antibodies, a high proportion were classified as dcSSc (66.6%) and a lower proportion were classified as lcSSc (29.4%). Lung fibrosis was most frequent in the anti-scleroderma-70 subgroup (62.2%) compared with other antibody subsets (22.3–41.9%). Gastrointestinal manifestations showed a similar high proportion in all antibody subgroups, except for patients who were anti-US ribonucleoprotein positive. The frequencies of PAH and kidney manifestations were generally similar across the antibody subsets, although the proportion among patients with anti-US ribonucleoprotein was slightly higher; heart manifestations were highest in patients with anti-scleroderma-70 and anti-U1 ribonucleoprotein and lowest in patients with ACA (table 2). The proportion of patients with previous digital ulcer complications and interventions was broadly similar in the anti-scleroderma-70 subgroup and the ACA subgroup; the most marked exception was for surgical amputation, which occurred almost twice as frequently in patients with ACA (14.6%) compared with anti-scleroderma-70-positive patients (7.9%) (table 3).

### Onset of disease manifestations by antibody status

In anti-scleroderma-70-positive patients, the first digital ulcer occurred at a mean age of 44.7 years (95% CI 43.6 to 45.7),...
The findings of the DUO Registry regarding the burden of disease in SSc patients with digital ulcers confirm the findings of other large cohort studies.\(^1\)\(^4\) Organ manifestations are common, with gastrointestinal manifestations being the most frequently reported, followed by lung fibrosis, PAH and heart manifestations.

Complications associated with digital ulcers, such as infection requiring systemic antibiotics, gangrene and amputation occurred frequently in all major SSc subsets. Anti-scleroderma-70-positive patients were younger at the onset of the first digital ulcer and had approximately double the rate of lung fibrosis compared with ACA-positive patients, these data are in line with findings from the European League Against Rheumatism Scleroderma Trials and Research.\(^4\) Furthermore, heart manifestations were also more common in the anti-scleroderma-70-positive group. Taken together, these findings confirm the association between anti-scleroderma-70 and more severe disease seen in other studies.\(^1\)

The data show that anti-scleroderma-70-positive patients have fewer surgical amputations than ACA-positive patients but more autoamputation. As patients with this antibody have more SSc disease manifestations, the physician may be more reluctant to perform surgical interventions with the patient being more likely to be left to autoamputation; whereas ACA-positive patients may have a phenotype that leads to a decision to amputate surgically.

The proportion of anti-U1 ribonucleoprotein in patients with SSc, at approximately 30% in both lcSSc and dcSSc, was much higher than the previously reported figures.\(^1\) In contrast to other studies, the presence of anti-U1 ribonucleoprotein did not appear to have a greater association with PAH or with gastrointestinal manifestations than other autoantibodies.\(^1\)

The proportion of patients reported here as anti-U3 ribonucleoprotein positive was low (4.9%), a finding similar to that reported in other studies.\(^1\) In addition, the complications associated with anti-U3 ribonucleoprotein positivity were similar as in previous studies.\(^6\)-\(^10\)

There are a number of limitations in this study. The DUO Registry is an observational study and not all data fields were completed for every patient; for example, the number of digital ulcers at enrolment was missing for 62 patients and few patients were tested for anti-RNA polymerase 3 or for anti-U3 ribonucleoprotein antibodies. Central testing was not performed and therefore potential variations between different analysis methods should be considered when interpreting the data.

In addition, at enrolment, differential recall bias for data recorded in the past may confound interpretation.

Almost half of all patients were being treated with bosentan. This is likely to be a reflection of the fact that the DUO Registry was initiated following EMA approval of bosentan,\(^2\) and it is possible that patient entry into the registry was biased towards patients receiving bosentan. Therefore, there are limitations...
### Table 3

Previous digital ulcer complications and interventions by antibody status

<table>
<thead>
<tr>
<th>Antibody Subsets</th>
<th>Previous digital ulcer complications</th>
<th>Previous critical digital ischaemia, n/N* (%)</th>
<th>Previous soft tissue infection requiring systemic antibiotics, total, n/N* (%)</th>
<th>Previous hospitalisation for digital ulcer, n/N* (%)</th>
<th>Previous upper limb sympathectomy, n/N* (%)</th>
<th>Previous digital sympathectomy, n/N* (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Scl-70 (N=854)</td>
<td>462/775 (59.6) (56.1 to 63.1)</td>
<td>174/340 (51.2) (45.7 to 56.6)</td>
<td>10/19 (52.6) (22.8 to 82.8)</td>
<td>187/340 (54.9) (48.7 to 61.2)</td>
<td>2.1 (1.5 to 2.8)</td>
<td>2.0 (1.1 to 3.2)</td>
</tr>
<tr>
<td>Anti-U1 RNP (N=120)</td>
<td>62/113 (54.9) (45.2 to 64.2)</td>
<td>13/26 (50.0) (27.8 to 70.7)</td>
<td>1/2 (50.0) (0.0 to 100.0)</td>
<td>7/23 (30.4) (13.2 to 50.0)</td>
<td>0.9 (0.0 to 10.3)</td>
<td>0.8 (0.0 to 3.2)</td>
</tr>
<tr>
<td>Anti-U3 RNP (N=39)</td>
<td>411/707 (58.1) (54.4 to 61.8)</td>
<td>9/29 (31.0) (15.3 to 47.9)</td>
<td>1/3 (33.3) (0.0 to 66.7)</td>
<td>2/8 (25.0) (0.0 to 50.0)</td>
<td>0.9 (0.0 to 6.3)</td>
<td>0.2 (0.0 to 5.0)</td>
</tr>
<tr>
<td>Anti-RNA Pol 3 (N=86)</td>
<td>15/36 (41.7) (25.5 to 59.2)</td>
<td>1/8 (12.5) (0.0 to 37.5)</td>
<td>1/1 (100.0) (0.0 to 100.0)</td>
<td>3/10 (30.0) (0.0 to 60.0)</td>
<td>1.0 (0.0 to 37.5)</td>
<td>0.0 (0.0 to 3.2)</td>
</tr>
</tbody>
</table>

---

**REFERENCES**

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry

Christopher P Denton, Thomas Krieg, Loic Guillemin, Barbara Schwierin, Daniel Rosenberg, Mariabeth Silkey, Maurice Zultak and Marco Matucci-Cerinic

Ann Rheum Dis published online January 12, 2012

Updated information and services can be found at:
http://ard.bmj.com/content/early/2012/01/12/annrheumdis-2011-200631

These include:

Supplementary Material
Supplementary material can be found at:
http://ard.bmj.com/content/suppl/2012/01/12/annrheumdis-2011-200631.DC1

References
This article cites 9 articles, 1 of which you can access for free at:
http://ard.bmj.com/content/early/2012/01/12/annrheumdis-2011-200631#ref-list-1

Open Access
This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (659)
Connective tissue disease (4253)
Immunology (including allergy) (5144)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/